Article in Molecules (Basel, Switzerland), 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 3 papers.
0numbers the graph read from it
0cells of the map it votes in
3citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
2 · The registry
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
5 · Who and what money
Authors and funding
11 authors.
Párástu OskoeiCESAM-Centre for Environmental and Marine Studies, Department of Biology, University of Aveiro, Campus Universitário de Santiago, 3810-193 Aveiro, Portugal.ORCID 0000-0002-4159-0444
Rúben AfonsoCESAM-Centre for Environmental and Marine Studies, Department of Biology, University of Aveiro, Campus Universitário de Santiago, 3810-193 Aveiro, Portugal.
Verónica BastosCESAM-Centre for Environmental and Marine Studies, Department of Biology, University of Aveiro, Campus Universitário de Santiago, 3810-193 Aveiro, Portugal.ORCID 0000-0002-9882-4766
João NogueiraCICECO-Aveiro Institute of Materials, Department of Chemistry, University of Aveiro, Campus Universitário de Santiago, 3810-193 Aveiro, Portugal.ORCID 0000-0002-3193-2703
Lisa-Marie KellerFederal Institute for Material Research Testing (BAM), Unter den Eichen 87, 12205 Berlin, Germany.
Elina AndresenFederal Institute for Material Research Testing (BAM), Unter den Eichen 87, 12205 Berlin, Germany.
Maysoon I SalehFederal Institute for Material Research Testing (BAM), Unter den Eichen 87, 12205 Berlin, Germany.
Bastian RühleFederal Institute for Material Research Testing (BAM), Unter den Eichen 87, 12205 Berlin, Germany.ORCID 0000-0003-3383-9999
Ute Resch-GengerFederal Institute for Material Research Testing (BAM), Unter den Eichen 87, 12205 Berlin, Germany.
Ana L Daniel-da-SilvaCICECO-Aveiro Institute of Materials, Department of Chemistry, University of Aveiro, Campus Universitário de Santiago, 3810-193 Aveiro, Portugal.ORCID 0000-0001-6581-8880
Helena OliveiraCESAM-Centre for Environmental and Marine Studies, Department of Biology, University of Aveiro, Campus Universitário de Santiago, 3810-193 Aveiro, Portugal.ORCID 0000-0002-4673-0696
Funding
FCT/MCTES (PIDDAC) LA/P/0006/2020 (DOI 10.54499/LA/P/0006/2020)FCT/MCTES (PIDDAC) UIDB/50011/2020 (DOI 10.54499/UIDB/50011/2020)FCT/MCTES (PIDDAC) UIDP/50011/2020 (DOI 10.54499/UIDP/50011/2020)Federal Institute For Materials Research and Testing internal project nanoplatformFEDER and FCT/MCTES PTDC/BTM-MAT/31794/2017 (POCI-01-0145-FEDER-031794)Fundação para a Ciência e Tecnologia 10.54499/CEECIND/04050/2017/CP1459/CT0023Fundação para a Ciência e Tecnologia 2022.11644.BD (doi.org/10.54499/2022.11644.BD)Fundação para a Ciência e Tecnologia CDL-CTTRI-54-SGRH/2022 and DOI 10.54499/2022.05740.CEECIND/CP1720/CT0031Fundação para a Ciência e Tecnologia CEECIND/03075/2018/CP1559/CT0020 (DOI: 10.54499/CEECIND/03075/2018/CP1559/CT0020)Fundação para a Ciência e Tecnologia SFRH/BD/146249/2019Fundação para a Ciência e Tecnologia UID/50006 + LA/P/0094/2020 (doi.org/10.54499/LA/P/0094/2020)
6 · The paper itself
Abstract
Melanoma is one of the most aggressive skin cancers and requires innovative therapeutic strategies to overcome the limitations of conventional therapies. In this work, upconversion nanoparticles coated with mesoporous silica and functionalized with folic acid (UCNP@mSiO
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.
Upconversion Nanoparticles with Mesoporous Silica Coatings for Doxorubicin Targeted Delivery to Melanoma Cells. · full record | OpenQuestion